Dexpramipexole dihydrochloride Size:Solid 10 mg Smiles: CC1C=CC(CN(CC2C=CC(=CC=2)C2=CC=CC=C2S(=O)(=O)NC#N)C(=O)C2=CC=CC=C2Cl)=CC=1

Smiles: CC1C=CC(CN(CC2C=CC(=CC=2)C2=CC=CC=C2S(=O)(=O)NC#N)C(=O)C2=CC=CC=C2Cl)=CC=1

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

PubMed PMID: 26364611

is an inhibitor of the selenoenzyme glutathione peroxidase used to treat active rheumatoid arthritis and juvenile idiopathic arthritis

Dexpramipexole dihydrochloride Size:Solid 10 mg Smiles: CC1C=CC(CN(CC2C=CC(=CC=2)C2=CC=CC=C2S(=O)(=O)NC#N)C(=O)C2=CC=CC=C2Cl)=CC=1Dexpramipexole, also known as KNS 760704 and (R) Pramipexole, is under development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. Dexpramipexole is a low molecular weight, water soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well